A study to evaluate the effects and safety of INCA033989 in participants with myelofibrosis or essential thrombocythemia
INCA 33989-101
Phase 1 other active
Quick answer
A study to evaluate the effects and safety of INCA033989 in participants with myelofibrosis or essential thrombocythemia for Myeloproliferative Neoplasms is a Phase 1 program (other) at Incyte Biosciences Distribution B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Incyte Biosciences Distribution B.V.
- Indication
- Myeloproliferative Neoplasms
- Phase
- Phase 1
- Modality
- other
- Status
- active